57
Views
5
CrossRef citations to date
0
Altmetric
Reports

Black Tea-Induced Decrease in IL-10 and TGF-β of Tumor Cells Promotes Th1/Tc1 Response in Tumor Bearer

, , , , &
Pages 213-221 | Received 25 Jan 2007, Published online: 05 Dec 2007
 

Abstract

Several lines of evidence support that impairment of host immune function by tumor may be related to several strategies of tumor escape from immunosurveillance. We found that in Ehrlich's ascites carcinoma (EAC)-bearing mice, the tumor cells secrete immunosuppressive cytokines, transforming growth factor beta (TGF-β) and interleukin-10 (IL-10) that induce a general T helper cells type 2 (Th2) dominance dampening the T cytotoxic cells type 1 (Tc1) population. Interestingly, black tea at the antitumor dose of 2.5% significantly reduced TGF-β and IL-10 in tumor cells in vivo, thereby preventing Th2 dominance in the tumor bearers and initiating a Th1/Tc1 response. Thus, apart from its anticancer activity, this popular beverage also rejuvenates cancer immunosurveillance by modulating cytokine profiles and establishing Th1/Tc1 dominance in the tumor-bearing host.

Acknowledgments and Notes

We thank Mr. Uttam K. Ghosh, Mr. Somnath Chakraborty, and Mr. Ranjan K. Dutta for technical assistance and National Tea Research Foundation, India, for financial support. We are grateful to CSIR, India and UGC, India for fellowships and contingent grants.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.